



# Astragalus polysaccharides inhibit avian infectious bronchitis virus infection by regulating viral replication

Pengju Zhang<sup>a,1</sup>, Xuefeng Liu<sup>b,1</sup>, Haiyan Liu<sup>a</sup>, Weixia Wang<sup>a</sup>, Xiaohui Liu<sup>a</sup>, Xintao Li<sup>a,\*</sup>, Xinghong Wu<sup>a,\*\*</sup>

<sup>a</sup> Institute of Animal Sciences, Jilin Academy of Agricultural Sciences, #1363 Shengtai Street, Changchun 130124, Jilin Province, PR China

<sup>b</sup> Heilongjiang Animal Science Institute, #2 Heyi Street, Qiqihaer 161005, Heilongjiang Province, PR China

## ARTICLE INFO

### Keywords:

Astragalus polysaccharides  
Infectious bronchitis  
Infectious bronchitis virus  
Cytokines  
Antiviral effects

## ABSTRACT

The avian coronavirus causes infectious bronchitis (IB), which is one of the most serious diseases affecting the avian industry worldwide. However, there are no effective strategies for controlling the IB virus (IBV) at present. Therefore, development of novel antiviral treatment strategies is urgently required. As reported, astragalus polysaccharides (APS) have potential antiviral effects against several viruses; however, the antiviral effect of APS against IBV remains unclear. In this study, we explored whether APS had the potential to inhibit IBV infection by utilizing several *in vitro* experimental approaches. To this end, the effect of APS on the replication of IBV was examined in chicken embryo kidney (CEK) cells. Viral titers were calculated by using the plaque formation assay, and the cytotoxicity of APS was tested by utilizing a Cell Counting Kit-8 assay. The expression of viral mRNA and cytokine (IL-1 $\beta$ , IL-6, IL-8 and TNF- $\alpha$ ) mRNA transcripts was determined by real-time quantitative RT-PCR (qRT-PCR). IBV titers in infected CEK cells treated with APS were significantly reduced in a dose-dependent manner, indicating that APS inhibited IBV replication *in vitro*. We also found that the decreased viral replication after APS treatment was associated with reduced mRNA levels of the cytokines *IL-1B*, *IL-6*, *IL-8* and *TNF- $\alpha$* . In conclusion, these results suggest that APS exhibit antiviral activities against IBV and it may represent a potential therapeutic agent for inhibiting the replication of IBV.

## 1. Introduction

Avian infectious bronchitis virus (IBV), a member of the *Coronaviridae* family, causes mild-to-acute respiratory disease in chickens and leads to huge economic losses in the poultry industry worldwide [1,2]. More than 50 serotypes of IBV have been documented since the first virus was isolated from birds exhibiting respiratory symptoms in the United States in 1931 [3]. Extensive genetic diversity of IBV strains worldwide renders vaccines largely ineffective, because of poor or no cross-protection between different IBV serotypes [4,5]. Thus, finding an effective antiviral drug or agent is imperative for the prevention of IBV infection.

The Chinese government has prohibited the use of antiviral drugs in food animals in China; thus, utilization of traditional antiviral herbs remains a major focus. Several reports have confirmed that traditional Chinese herbs effectively inhibit the replication of various viruses [6–8]. Astragalus polysaccharides (APS), isolated from a traditional

Chinese medicinal herb, *Astragalus mongholicus*, have been widely used immunopotentiators [9–11]. Recently, several studies have shown that supplementation with APS can inhibit replication of several animal viruses, including H9N2 avian influenza virus [12], foot and mouth disease virus [13], Newcastle disease virus [14], and infectious bursal disease virus [15]. However, the effect of APS on IBV replication remains unclear. Therefore, in this study, we investigated the antiviral effects of APS against IBV by utilizing several *in vitro* approaches.

## 2. Materials and methods

### 2.1. Virus, cells, and APS

The IBV strain M41 (China Institute of Veterinary Drug Control) was adapted and propagated in chicken embryo kidney (CEK) cells. The CEK cell monolayers were maintained in Dulbecco's modified Eagle's medium (DMEM, Gibco, USA) supplemented with 10% fetal bovine

\* Corresponding author.

\*\* Corresponding author.

E-mail addresses: [lixintao2005@126.com](mailto:lixintao2005@126.com) (X. Li), [wxhcajss@126.com](mailto:wxhcajss@126.com) (X. Wu).

<sup>1</sup> These authors contributed equally to this study.

serum (FBS; HyClone, Logan, UT, USA), 100 units/mL penicillin, 100 µg/ml streptomycin, and 2 mM L-glutamine in a humidified chamber, supplemented with 5% CO<sub>2</sub>, at 37 °C.

APS (net content, 95.9%) brought from Sihai Plant Extracts Co., Ltd (Nantong, China) were dissolved in deionized water and diluted to 1, 5, 10, 20, 30, and 50 µg/ml. The APS solution was sterilized by heat treatment (100 °C for 30 min), and then stored at -4 °C until use.

## 2.2. Cytotoxicity assay

Cytotoxicity was determined by using a Cell Counting Kit-8 (CCK8; Donjindo, Japan) according to the manufacturer's instructions. Briefly, the CEK cells were seeded into 96-well culture plates, at a density of  $1 \times 10^4$  cells/well, and incubated at 37 °C in a 5% CO<sub>2</sub> incubator for 24 h. After washing with PBS, three times, APS at various concentrations (1, 5, 10, 20, 30, or 50 µg/mL) were added to the wells. The cells were then cultured for a further 48 h. Mock-treated cells served as controls. After washing with PBS, the CEK cells were incubated with CCK8 solution at 37 °C for 4 h. Absorbance was measured at 450 nm by using a QuantUniversal Microplate Spectrophotometer (BioTek Instruments, Inc., Winooski, VT, USA). The relative cell viability rate was determined for each concentration based on the following formula:  $(OD_{450} \text{ drug}) / (OD_{450} \text{ control}) \times 100\%$ . APS concentrations below the 50% cytostatic concentration (CC<sub>50</sub>) were defined as non-toxic concentrations [16].

## 2.3. Virus titration and infection

To calculate viral titers (infectivity), a plaque-formation assay was performed. Briefly,  $2 \times 10^5$  CEK cells seeded into 24 wells tissue culture dishes were grown until 100% confluence, and then inoculated with serially diluted IBV ( $10^{-1}$ - $10^{-6}$ ). Subsequently, overlay medium (1% low-melting-point agarose with DMEM containing 10% FBS) was added to each well and further incubated at 37 °C, 5% CO<sub>2</sub>, for 72 h. The cells were subsequently stained with gentian violet (1% crystal violet, 10% formaldehyde and 5% EtOH in PBS). The virus titer was determined by counting the number of plaques formed at a specific dilution, as described by Dove et al. [17].

## 2.4. Treatment of infected cells with APS

To analyze the effect of APS on infected cells, CEK cell monolayers were infected with IBV at  $2 \times 10^6$  plaque-forming units/ml, and subsequently incubated at 37 °C for 1 h. Cell monolayers were then washed three times with PBS, and the infected cells were treated with various concentrations of APS (1, 5, 10, 20, or 30 µg/mL). Mock cells and infected cells represented negative and positive controls, respectively. After 24 h, CEK cell lysates were prepared for subsequent plaque assays.

## 2.5. Real time quantitative RT-PCR (qRT-PCR)

Genomic and subgenomic RNA levels of IBV in mock and virus-infected CEK cells treated with different concentration of APS were quantified by TaqMan real-time RT-PCR as described previously [18].

To quantify the expression of cytokines (*IL-1β*, *IL-6*, *IL-8* and *TNF-α*), total RNA was extracted from cultured cells using Trizol reagent (Takara Biotechnology, Dalian, China) according to the manufacturer's instructions. Total RNA purity and concentration were measured by using ultraviolet spectrophotometry (Life Technologies, Carlsbad, CA, USA). The isolated RNA was digested with DNase1 (Takara Biotechnology, Dalian, China) at 37 °C for 30 min cDNA was synthesized from total RNA using a PrimeScript RT Reagent Kit (TaKaRa). Amplifications were performed with 0.5 µL cDNA, in a total volume of 10 µL, using SYBR Green Real-Time PCR MasterMix (Roche, Mortlake, Australia), in a 7900HT Fast Real-Time PCR System (Applied Biosystems, Shanghai, China), according to the manufacturer's

**Table 1**

Real time PCR primers used for mRNA expression analysis.

Target gene	Prime (5'-3')
IL-1β	F-GGGCATCAAGGGCTACAA R-CTGTCCAGGCGGTAGAAGAT
IL-6	F-AGAAATCCCTCCTCGCCAAT R-AAATAGCGAAGCGCCCTCA
IL-8	F-GCCCTCCTCCTGGTTTCAG R-TGGCACCGCAGCTCAIT
IFNα	F-GACAGCCAACGCCAAAGC R-GTCGCTGCTGTCCAAGCATT
GAPDH	F-TGCCAACGTGTCGGTTGT R-TGTCATCATATTTGGCAGGTTT

Abbreviations: F, forward; mRNA, messenger RNA; PCR, polymerase chain reaction; R, reverse.

instruction. The primers for cytokine genes and *GAPDH* used in this study are listed in Table 1. Cytokine gene expression was normalized to that of *GAPDH* using the  $2^{-\Delta\Delta Ct}$  method.

## 2.6. Western blots

Total protein was extracted from cultured CEK cells using a modified radioimmunoprecipitation assay buffer supplemented with protease inhibitor cocktail (Beyotime, Shanghai, China). Protein concentrations were determined using a BCA protein assay kit (Pierce, Rockford, IL, USA). Equal amounts of protein were separated on a 10% SDS polyacrylamide gel and electro-transferred from the gel to a polyvinylidene fluoride (PVDF) membrane (Amersham Bioscience, USA). After blocking with 5% non-fat milk in PBS, the membrane was probed with chicken anti-nucleocapsid polyclonal antibody (diluted 1:1000) and chicken anti-GAPDH polyclonal antibody (diluted 1:5000) overnight, followed by incubation with horseradish peroxidase-conjugated secondary antibodies for 1 h at room temperature. GAPDH was used as the internal loading control. The protein bands were detected using a chemiluminescent substrate kit (Millipore Company, Bedford, MA, USA), according to the manufacturer's instructions.

## 2.7. Statistical analyses

All results are represented as mean  $\pm$  standard deviation (SD) from at least three independent experiments. All statistical analysis was performed using SPSS 19 software package (SPSS Inc; Chicago, IL, USA). One-way ANOVA with Bonferroni's post-hoc tests were performed to compare the differences among three or more groups. Differences were considered significant at  $p < 0.05$ .

## 3. Results

### 3.1. The cytotoxic effect of APS on CEK cell proliferation

To investigate whether APS treatment affects cell viability, the toxicity of APS on CEK cells was determined using the CCK8 method. At concentrations of 5 µg/ml and 10 µg/ml, only 12.1% and 18.3% of CEK cells were killed after 48 h, respectively (Fig. 1). At 30 µg/ml, APS killed 47.6% of cells, whereas the viability was below 50% after treatment with APS at 50 µg/ml. These results indicate that APS did not influence cell viability at concentrations below 30 µg/ml, and therefore this concentration was chosen as the maximum concentration of APS for the antiviral assays.

### 3.2. APS inhibit IBV replication in vitro

The antiviral activity of APS against IBV was determined by plaque formation assay. As showed in Fig. 2A, virus titers significantly decreased in infected CEK cells treated with APS, in a dose-dependent

Download English Version:

<https://daneshyari.com/en/article/8749863>

Download Persian Version:

<https://daneshyari.com/article/8749863>

[Daneshyari.com](https://daneshyari.com)